Implantable chip to test chemo in pancreatic cancer surgery
Part of Cancer, Digestive system, Hormones & metabolism clinical trials.
This trial tests a tiny implantable device that measures how different chemotherapy drugs work on your tumor during surgery. The goal is to find the most effective treatment for your specific cancer.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 years or older
- You have a pancreatic tumor that needs surgery (like a Whipple procedure)
- The surgeon thinks the device can be safely placed in your tumor during the operation
- You are not pregnant and agree to use birth control if applicable
- You have not had another cancer that could interfere with this study
- Your tumor has not spread to other parts of the body (not metastatic or locally advanced)
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new drug called mitazalimab injected directly into the tumor, combined with a special electrical procedure that kills cancer cells. It is for people whose pancreatic cancer has not spread but cannot be removed by surgery.
This trial tests whether adding focused ultrasound (IMD10) to standard chemotherapy helps treat pancreatic cancer that is borderline or locally advanced and cannot be removed by surgery right away. It may shrink the tumor enough to allow surgery later.
This Phase 2 trial tests a chemotherapy plan given before surgery (called “neoadjuvant” treatment) for people with pancreatic adenocarcinoma that looks resectable or borderline resectable on scans. The goal is to see how well this adaptive chemotherapy approach works and whether it can improve outcomes before an operation.
This trial tests a new treatment, PTM-101, placed during a laparoscopy procedure for people with pancreatic cancer that can be removed with surgery. It aims to see if adding this treatment before standard chemotherapy helps improve outcomes.
This trial tests a new drug combination for pancreatic cancer that has not been treated before. It may help shrink tumors or make surgery possible for people with advanced or borderline resectable disease.
This trial tests a new immunotherapy drug called ivonescimab combined with chemotherapy, with or without another experimental drug (AK117), for people with pancreatic cancer that has spread. The goal is to see if adding these therapies can help shrink tumors or slow the cancer's growth.
Hear when a new Pancreatic cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.